Free Trial

Crinetics Pharmaceuticals (CRNX) News Today

Crinetics Pharmaceuticals logo
$30.59 +0.07 (+0.23%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$30.66 +0.07 (+0.25%)
As of 05/30/2025 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRNX Latest News

Crinetics Pharmaceuticals, Inc. stock logo
Universal Beteiligungs und Servicegesellschaft mbH Invests $17.12 Million in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 334,783 shares of the company's stock, valued at ap
Crinetics Pharmaceuticals, Inc. stock logo
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 53,529 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 19.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The i
Crinetics Pharmaceuticals, Inc. stock logo
Woodline Partners LP Makes New $2.56 Million Investment in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Woodline Partners LP acquired a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 50,000 shares of the company's st
Crinetics Pharmaceuticals, Inc. stock logo
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Position Lessened by D. E. Shaw & Co. Inc.
D. E. Shaw & Co. Inc. reduced its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 85.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,876 shares of the company's stock after s
Crinetics Pharmaceuticals, Inc. stock logo
Nuveen Asset Management LLC Boosts Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Nuveen Asset Management LLC raised its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 2.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 527,792 shares of the company's stock af
Crinetics Pharmaceuticals, Inc. stock logo
Bank of America Corp DE Decreases Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Bank of America Corp DE decreased its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 15.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 235,281 shares of the company's stock after selling 4
Crinetics Pharmaceuticals, Inc. stock logo
ProShare Advisors LLC Acquires 9,655 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
ProShare Advisors LLC grew its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 49.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 29,089 shares of the company's stock after purchasing an additional 9,655 shares during
Crinetics Pharmaceuticals, Inc. stock logo
85,000 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Purchased by Soleus Capital Management L.P.
Soleus Capital Management L.P. bought a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 85,000 shares of the company's s
Crinetics Pharmaceuticals, Inc. stock logo
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Rafferty Asset Management LLC
Rafferty Asset Management LLC lowered its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 16.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 81,257 shares of the company's stock after
Crinetics Pharmaceuticals, Inc. stock logo
Tema Etfs LLC Takes Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Tema Etfs LLC purchased a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 57,933 shares of the company's stock, valued at approximately $2,962,000. Crinetics Pharmaceuticals acco
Crinetics Pharmaceuticals, Inc. stock logo
Ameriprise Financial Inc. Purchases 186,681 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Ameriprise Financial Inc. raised its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 110.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 355,174 shares of the company's stock a
Crinetics Pharmaceuticals, Inc. stock logo
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Acquired by Point72 Asset Management L.P.
Point72 Asset Management L.P. lifted its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 21.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,788,939 shares of the company's stock after buying an a
Crinetics Pharmaceuticals, Inc. stock logo
MPM Bioimpact LLC Purchases 91,190 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
MPM Bioimpact LLC lifted its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 17.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 617,035 shares of the company's stock after purchasing an a
Crinetics Pharmaceuticals, Inc. stock logo
Parkman Healthcare Partners LLC Reduces Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Parkman Healthcare Partners LLC lowered its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 34.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 51,133 shares of the com
Crinetics Pharmaceuticals, Inc. stock logo
Paradigm Biocapital Advisors LP Sells 605,925 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Paradigm Biocapital Advisors LP reduced its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 24.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 1,910,761 shares of the company's stock after selling 605,925 shares du
Crinetics Pharmaceuticals, Inc. stock logo
Cantor Fitzgerald Weighs in on CRNX FY2025 Earnings
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) - Research analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for shares of Crinetics Pharmaceuticals in a report issued on Monday, May 12th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post ea
Crinetics Pharmaceuticals, Inc. stock logo
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Holdings Lifted by Nicholas Investment Partners LP
Nicholas Investment Partners LP boosted its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 35.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 127,283 shares of the company's stock af
Crinetics Pharmaceuticals, Inc. stock logo
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Orbimed Advisors LLC
Orbimed Advisors LLC trimmed its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 4.9% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 999,000 shares of the company's stock after selling 51,055 shares during th
Crinetics Pharmaceuticals, Inc. stock logo
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by Janus Henderson Group PLC
Janus Henderson Group PLC lifted its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 15.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,795,441 shares of the company's stock after purchasing
Crinetics Pharmaceuticals, Inc. stock logo
Ensign Peak Advisors Inc Sells 114,147 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Ensign Peak Advisors Inc reduced its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 18.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 502,690 shares of the company's stock aft
Crinetics Pharmaceuticals, Inc. stock logo
Brevan Howard Capital Management LP Takes $500,000 Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Brevan Howard Capital Management LP bought a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 9,777 shares of the company's stock, valued at approximately $500,000. Several ot
Crinetics Pharmaceuticals, Inc. stock logo
Algert Global LLC Lowers Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Algert Global LLC cut its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 32.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 28,777 shares of the company's stock aft
Crinetics Pharmaceuticals, Inc. stock logo
Farallon Capital Management LLC Boosts Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Farallon Capital Management LLC raised its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 250.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,075,098 shares o
Crinetics Pharmaceuticals, Inc. stock logo
Northern Trust Corp Has $44.99 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Northern Trust Corp lifted its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 20.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 879,814 shares of the company's stock after purchasing an additional
Crinetics Pharmaceuticals, Inc. stock logo
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stake Increased by Driehaus Capital Management LLC
Driehaus Capital Management LLC grew its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 4.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,141,014 shares of the company's stock after purchasing an
Crinetics Pharmaceuticals, Inc. stock logo
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.
Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). In a filing disclosed on May 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Crinetics Pharmaceuticals stock on April 17th. The trad
Crinetics Pharmaceuticals, Inc. stock logo
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) have earned an average rating of "Moderate Buy" from the thirteen ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and twelve have issued a buy re
Crinetics Pharmaceuticals, Inc. stock logo
Duquesne Family Office LLC Cuts Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Duquesne Family Office LLC trimmed its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 60.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 122,700 shares of the company's
Crinetics Pharmaceuticals, Inc. stock logo
The Manufacturers Life Insurance Company Raises Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
The Manufacturers Life Insurance Company boosted its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 11.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 148,956 shares of the company's stock
Crinetics Pharmaceuticals, Inc. stock logo
Allostery Investments LP Acquires Shares of 9,700 Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Allostery Investments LP bought a new position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 9,700 shares of the company's stock, valued at a
Crinetics Pharmaceuticals, Inc. stock logo
Acuta Capital Partners LLC Sells 8,800 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Acuta Capital Partners LLC decreased its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 6.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 122,900 shares of the com
Crinetics Pharmaceuticals, Inc. stock logo
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Novo Holdings A S
Novo Holdings A S decreased its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 4.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 960,215 shares of the company's stock after selling 39,785 shares du
Crinetics Pharmaceuticals, Inc. stock logo
Crinetics Pharmaceuticals (CRNX) to Release Quarterly Earnings on Thursday
Crinetics Pharmaceuticals (NASDAQ:CRNX) will be releasing its Q1 2025 earnings after the market closes on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-crinetics-pharmaceuticals-inc-stock/)
Crinetics Pharmaceuticals, Inc. stock logo
Schonfeld Strategic Advisors LLC Has $22.80 Million Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Schonfeld Strategic Advisors LLC decreased its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 9.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 445,946 shares of the company's stock after se
Crinetics Pharmaceuticals, Inc. stock logo
27,712 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Acquired by Aquatic Capital Management LLC
Aquatic Capital Management LLC acquired a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 27,712 shares of the company's stock
Crinetics Pharmaceuticals, Inc. stock logo
Adage Capital Partners GP L.L.C. Has $3.32 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Adage Capital Partners GP L.L.C. grew its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 62.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 65,000 shares of the com
Crinetics Pharmaceuticals, Inc. stock logo
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by First Trust Advisors LP
First Trust Advisors LP lowered its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 6.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 195,821 shares of the company's stock after selling
Crinetics Pharmaceuticals, Inc. stock logo
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Position Lowered by First Light Asset Management LLC
First Light Asset Management LLC trimmed its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 6.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 885,453 shares of the company's stock after selling 58,158
Crinetics Pharmaceuticals, Inc. stock logo
Boothbay Fund Management LLC Purchases 28,327 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Boothbay Fund Management LLC raised its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 25.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 137,752 shares of the
Crinetics Pharmaceuticals, Inc. stock logo
Gilder Gagnon Howe & Co. LLC Has $1.28 Million Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Gilder Gagnon Howe & Co. LLC grew its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 98.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 25,044 shares of the company's stock after acquiring an a
Crinetics Pharmaceuticals, Inc. stock logo
MetLife Investment Management LLC Acquires 8,085 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
MetLife Investment Management LLC boosted its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 18.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 53,020 shares of the company's stock
Get Crinetics Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.

CRNX Media Mentions By Week

CRNX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CRNX
News Sentiment

1.41

0.87

Average
Medical
News Sentiment

CRNX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CRNX Articles
This Week

7

7

CRNX Articles
Average Week

Get Crinetics Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:CRNX) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners